The REMATCH study randomly assigned 129 patients with Class IV end-stage heart failure who were ineligible for cardiac transplantation. Within the study, 68 patients received an LVAD and 61 patients received optimal medical management. Among the patients who received the LVAD, there was a reduction of 48 percent in the risk of death from any cause, compared with the medical-therapy group. Rates of survival among REMATCH study patients: + Survival rates among REMATCH study patients Time frame Patients with LVAD Patients receiving optimal medical therapy At 12 months 52% 25% At 24 months 23% 8% The frequency of serious adverse events in the LVAD group was 2.35 times that in the medical-therapy group, with a predominance of infection, bleeding and malfunction of the device. However, the quality of life was significantly improved at one year in the LVAD group.
Destination therapy
Antisense therapy
Aversion therapy
Differentiation therapy
Collaborative therapy
Cytoluminescent therapy
Sex therapy
Recreational therapy